Stockwinners Market Radar for April 05, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

GILD...

Hot Stocks

20:09 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Gilead Sciences (GILD) said it is donating 1.5M doses of its experimental anti-coronavirus drug remdesivir, which could treat 140,000 patients. In an open letter, Chairman and CEO Daniel O'Day said that the drug will be offered for compassionate use, expanded access and clinical trials, and will treat patients with severe symptoms. "Our existing supply, including finished product ready for distribution as well as investigational medicine in the final stages of production, amounts to 1.5 million individual doses. Depending on the optimal duration of treatment, which is something we are studying in clinical trials, this supply could equate to well over 140,000 treatment courses for patients. [...] Gilead is providing the entirety of this existing supply at no cost, to treat patients with the most severe symptoms of COVID-19. The 1.5 million individual doses are available for compassionate use, expanded access and clinical trials and will be donated for broader distribution following any potential future regulatory authorizations. These doses are for treating patients with severe symptoms, through daily intravenous infusions in a hospital setting. Having a potential treatment in our hands comes with significant responsibility." 2. Boeing (BA) announced that it is extending the temporary suspension of production operations at all Puget Sound area and Moses Lake sites until further notice. "These actions are being taken in light of the company's continuing focus on the health and safety of employees, current assessment of the spread of COVID-19 in Washington state, the reliability of the supply chain and additional recommendations from government health authorities," the plane maker said in a statement Sunday night. 3. Across the media landscape, advertising is disappearing, one more casualty of the global economic shutdown, and new technology won't be a savior as this is an equal-opportunity problem across print, TV, digital, radio, and outdoor advertising, Eric Savitz wrote in this week's edition of Barron's. Even the most prominent ad buyers lack reasons, and often the means, to buy ads, the author notes, while many of the small and medium-size businesses that buy online ads are struggling to stay solvent. Both Facebook (FB) and Twitter (TWTR) have already warned that they will take a hit from the downturn, and Alphabet's Google (GOOGL) no doubt is seeing the same effects, but so far hasn't discussed the matter, the publication adds. 4. United Airlines (UAL) is cutting nearly 90% of its New York-area flying, as public health officials predicted that the city will reach the peak of its novel coronavirus outbreak in the coming days, The Wall Street Journal's Alison Sider reported. The airline said the reductions set to remain in place for at least three weeks will mean substantially fewer employees will need to show up each day, though workers will continue to receive pay and benefits, the author noted. 5. Comcast (CMCSA), AT&T (T), Verizon (VZ), Abbott Laboratories (ABT), Chevron (CVX), Hormel Foods (HRL), Johnson & Johnson (JNJ), Kimberly-Clark (KMB), Medtronic (MDT), Procter & Gamble (PG), and T. Rowe Price (TROW) saw positive mentions in this week's edition of Barron's.
BA

Hot Stocks

18:10 EDT Boeing extends Seattle production suspension due to COVID-19 - Boeing announced that it is extending the temporary suspension of production operations at all Puget Sound area and Moses Lake sites until further notice. "These actions are being taken in light of the company's continuing focus on the health and safety of employees, current assessment of the spread of COVID-19 in Washington state, the reliability of the supply chain and additional recommendations from government health authorities," the plane maker said in a statement Sunday night. During the suspension, Boeing said it will continue to implement additional health and safety measures at its facilities to protect employees. These measures include new visual cues to encourage physical distancing, more frequent and thorough cleaning of work and common areas and staggering shift times to reduce the flow of employees arriving and departing work, among many other improvements. It added, "As the suspension of operations continues, Boeing will monitor government guidance and actions on COVID-19 and associated impact on all company operations. Boeing sites that remain open are being monitored and assessed on a daily basis."
MMM

Hot Stocks

17:30 EDT 3M responds to reporting on alleged seizure of N95 respirator shipments - 3M issued the following statement in response to media reports alleging a shipment of 3M personal protective equipment was seized and diverted by U.S. authorities on Friday, April 3, while in transit from a 3M China facility to Berlin Police: "3M has no evidence to suggest 3M products have been seized. 3M has no record of any order of respirators from China for the Berlin police. We cannot speculate where this report originated." According to the company's statement, 3M has extended an offer of help to the German authorities to try "to determine if this false report is the result of fraudulent activity. We have extended this offer to all countries seeking to verify the authenticity of offers to sell respirators. 3M is committed to combating any illegal activity in connection with our products and the COVID-19 outbreak and is working with law enforcement to identify and punish perpetrators."
GILD

Hot Stocks

15:13 EDT Gilead to donate experimental COVID-19 drug Remdesivir - Gilead Sciences said it is donating 1.5M doses of its experimental anti-coronavirus drug remdesivir, which could treat 140,000 patients. In an open letter, Chairman and CEO Daniel O'Day said that the drug will be offered for compassionate use, expanded access and clinical trials, and will treat patients with severe symptoms. "In addition to the expanded access programs, we continue to provide remdesivir on an individual compassionate use basis for children and pregnant women. More than 1,700 patients have now been treated through these programs. [...] As soon as we knew that remdesivir may have potential in treating the novel coronavirus, our teams began to establish a supply chain for large-scale production. Then, as now, there were many unknowns including how long the outbreak would last, at what scale and whether remdesivir is a safe and effective treatment for COVID-19. We made the decision to invest and scale up regardless, because if remdesivir was going to be needed for patients, we had to be ready. In the space of two months, we have significantly increased our available supply of remdesivir using the inventory of active pharmaceutical ingredients we already had on hand. Our existing supply, including finished product ready for distribution as well as investigational medicine in the final stages of production, amounts to 1.5 million individual doses. Depending on the optimal duration of treatment, which is something we are studying in clinical trials, this supply could equate to well over 140,000 treatment courses for patients.[...] Gilead is providing the entirety of this existing supply at no cost, to treat patients with the most severe symptoms of COVID-19. The 1.5 million individual doses are available for compassionate use, expanded access and clinical trials and will be donated for broader distribution following any potential future regulatory authorizations. These doses are for treating patients with severe symptoms, through daily intravenous infusions in a hospital setting. Having a potential treatment in our hands comes with significant responsibility. Providing our existing supplies at no charge is the right thing to do, to facilitate access to patients as quickly as possible and in recognition of the public emergency posed by this pandemic." Reference Link
INTU

Hot Stocks

14:02 EDT Intuit launches free Stimulus Registration product - TurboTax launched a free, Stimulus Registration product designed to help millions of Americans who are not required to file a tax return easily register with the IRS to get their stimulus money. According to the IRS, 80% of Americans are eligible to receive a stimulus payment. For the tens of millions of taxpayers, who have already filed a 2019 tax return or are Social Security Recipients, there is no action needed. They can easily find out how much they can expect to receive through the TurboTax Stimulus check calculator. For those tax filers, who have not yet filed a 2019 tax return, TurboTax recommends that they file their 2019 tax return now to get their tax refund and stimulus check quickly. This will ensure that the IRS has the most current tax filing and direct deposit information, which they will use to determine individual stimulus check amounts. There are as many as 10 million Americans who are not required to file a tax return. Because the IRS will use the federal tax return to determine eligibility and send individual stimulus payments, these individuals are at risk of not receiving their stimulus payment. In partnership with the IRS, TurboTax volunteered to create an innovative solution to help this group easily get their stimulus payment. "The TurboTax Stimulus Registration product was designed to help millions easily file a minimum tax return with the IRS, which has the information needed to determine their stimulus eligibility. Users simply answer a few questions and then choose to receive their payment via direct deposit or check," the company said in a statement.
AJX

Hot Stocks

13:57 EDT Great Ajax announces $80M private placement - Great Ajax announced that the company has entered into a securities purchase agreement pursuant to which it has agreed to issue and sell $80M of the company's preferred stock and warrants to affiliates of an institutional accredited investor in a private placement. The company will issue 1,200,000 shares of the company's 7.25% Series A Fixed-to-Floating Rate Preferred Stock, liquidation preference $25 per share, and 2,000,000 shares of the company's 5.00% Series B Fixed-to-Floating Rate Preferred Stock, liquidation preference $25 per share, each at a purchase price per share of $25 and two series of five-year warrants to purchase an aggregate of 4,000,000 shares of the company's common stock at an exercise price of $10 per share. Each series of warrants includes a put option that will allow the holder to sell the warrants to the company at a specified put price on or after July 6, 2023. In addition, the company has granted the investor an option to purchase up to an additional 300,000 shares of the company's Series A Preferred Stock, 500,000 shares of the company's Series B Preferred Stock and warrants to purchase an aggregate of 1,000,000 shares of the company's common stock on the same terms. The company expects to use the net proceeds from the private placement to acquire mortgage loans and mortgage-related assets consistent with the company's investment strategy.